Drug Information

Drug General Information
Drug ID
D0V4QS
Former ID
DAP000022
Drug Name
Olanzapine
Synonyms
Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Approved [467939], [535119]
Therapeutic Class
Antipsychotic Agents
Company
Eli Lilly
Structure
Download
2D MOL

3D MOL
Formula
C17H20N4S
InChI
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,18H,7-10H2,1-2H3
InChIKey
WXPNDRBBWZMPQG-UHFFFAOYSA-N
CAS Number
CAS 132539-06-1
PubChem Compound ID
4585
PubChem Substance ID
9530, 591970, 816938, 5025348, 7847520, 7980183, 11528747, 12014657, 14923451, 25819934, 26612730, 26719852, 26750094, 29215187, 29215188, 29223674, 42684855, 46386668, 46507666, 48416347, 49665994, 49666419, 49681733, 49830782, 53788662, 56310909, 56312010, 56312820, 56352944, 57288797, 57322337, 77029366, 81092909, 85174531, 85209215, 85213702, 85753333, 89736112, 92307994, 92308375, 92308920, 92712529, 93166490, 93167156, 93618268, 99637141, 103195217, 103950390, 104253651, 104306829
ChEBI ID
ChEBI:7735
SuperDrug ATC ID
N05AH03
SuperDrug CAS ID
cas=132539061
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Agonist [535119]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 467939(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 47).
Ref 535119Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61.
Ref 535119Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.